INTRODUCTION
Targeted therapy of juvenile idiopathic arthritis (JIA) with anti-TNFɑ biologics is efficacious with 70-80% responders and up to 50% achieving clinical inactivity on long term treatment [1, 2] . While sustained immune suppression through anti-TNFɑ is generally well tolerated, clinicians seek to achieve clinical remission off medication, to reduce risk of general infection, adverse events and financial burden [2] . Drug withdrawal in patients who attain clinical inactivity is complicated by the fact that 50-80% patients relapse upon therapy discontinuation [3, 4] . This phenomenon indicates that relapse patients who have attain clinical inactivity on medication, as defined by Wallace criteria, continue to experience subclinical inflammation and persistence of disease without overt presentation of clinical symptoms.
Conversely, patients who achieve clinical remission off medication could be spared long-term drug effects. As such, there is a clinical need to address how discontinuing anti-TNFɑ therapy can be safely implemented, and a scientific need to understand the immune mechanisms related to relapse.
The etiology of JIA remains widely debated [5] . Unsupervised genome wide association studies and pathway analysis have highlighted the role of CD4 T-helper cell populations in autoimmune disease progression [6] . CD4 T cells were shown to infiltrate the synovium microenvironment [7] [8] [9] [10] , and corresponding pathogenic CD4 HLA-DR + T-effector and regulatory subsets possessing strong immune phenotypic and TCR correlation with synovial T cells have been found re-circulating in the blood during active inflammation [11, 12] . Furthermore, epigenetic histone modifications associated with enhancer functions has been detected in CD4 T cells of JIA patients [13] . Using network analysis of DNA CpG methylation sites in total CD4 T cells, we have previously demonstrated that T-cell activation pathways are associated with Immunome perturbation in arthritic patients who relapse upon withdrawal 6 clinical fate upon anti-TNFɑ withdrawal [14] . However, the identity of the specific pathogenic CD4 subset that maintains subclinical disease persistence remains elusive.
We have leveraged on the high dimensional single cell resolution capabilities of Cytometry by Time-of-Flight (CyToF) to uncover the CD4 T cell subset responsible for disease persistence.
JIA patients who maintained clinical inactivity under anti-TNFɑ for at least 6 months, were subsequently withdrawn from therapy. These patients were rigorously scored for their disease progression across 8 months and their clinical outcome defined as relapse or remission. We interrogated the circulatory immunome of JIA patients prior to therapy withdrawal, and identified an inflammatory memory CD3 + CD4 + CD45RA -TNFɑ + T cell that is deficient for immune checkpoints (PD1 -CD152 -) in individuals who will relapse. Separately in patients who have flared after 8 months, this memory subset has extended towards TNFɑ + IL-6 + . We were able to use the memory CD3 + CD4 + CD45RA -TNFɑ + subset to discriminate relapse from remission patients prior to withdrawal, and cross validated this dysregulation against a larger cohort of healthy paediatric controls. Finally, transcriptomic profiling of CD4 memory cells reveal disease centric pathways that reflect selective divergence among relapse and remission patients. This study underscores immunological differences at the core of the dichotomic clinical responses. These differences provide a framework for understanding the mechanisms of disease relapse upon drug withdrawal, thus providing a knowledge-based guidance for management while proposing some potential new targets for intervention.
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MATERIALS AND METHODS

Samples
Peripheral blood mononuclear cells (PBMCs) were obtained from polyarticular JIA patients recruited through the "Determining Predictors of Safe Discontinuation of Anti-TNF treatment in JIA" trial (ID: NCT00792233) [15] . Patients were treated with anti-TNFɑ biologics and shown to be in an inactive disease state for 6 months, were enrolled into the study. was ≥ 30% worsening in more than three of the six JIA core parameters, and with no more than one parameter improving by > 30%. For remission individuals, they would have achieved ≥ 14 months of clinical inactivity from prior recruitment to study end. PBMCs were interrogated by CyToF from patients (n=20) prior to withdrawal were designated as (T o ), and separately from another batch (n=16) at the end of 8 months after withdrawal were designated as (T end ). Patient PBMCs (n=12) were also sorted for CD3 + CD4 + CD45RO + CD45RAfor Nanostring analysis.
The demographics/medication history profile of JIA patients withdrawn from therapy and sample usage breakdown is as shown (online supplementary Table S1).
Immunome perturbation in arthritic patients who relapse upon withdrawal 8 Age-matched healthy controls (n=69) were recruited through the Precision Rheumatology International Platform (PRIP) study conducted at the KK Women's and Children's Hospital (KKH). These controls have no indication of inflammation and PBMCs were isolated preoperatively from patients scheduled for day surgeries. Healthy PBMCs were examined with CyToF (n=10), Nanostrong (n=3) or age-matched strata cross validation for ROC curve (n=56).
Paired treatment naïve/post treatment JIA patients (n=4) were also recruited through the study "A precision medicine approach to understand and predict responsiveness to therapy in human arthritis" conducted in KKH for Nanostring analysis. These patients with active JIA were initially treatment naive to anti-TNFɑ, and after a 6-month drug course exhibited treatment susceptibility determined by complete absence of active joints. The demographics/medication history profile of JIA patients is as shown (online supplementary Table S2 ).
Additional methodological details are available as supplementary information.
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RESULTS
CD4 + CD45RA -TNFɑ + T cells is present in JIA patients prior to relapse
Dsyregulated CD4 T cells are thought to contribute to JIA pathogenesis [7] [8] [9] [10] [11] [12] . We interrogated the circulatory CD4 landscape of JIA patients (n=20) prior to therapy withdrawal to understand why certain individuals relapse. At this stage, the patients are clinically scored to be inactive for 6 months, thus patients who will relapse or remain in remission are clinically indistinguishable prior to withdrawal. We assessed the PBMCs with a CyToF panel consisting of 31 functional, 6 lineage markers (online supplementary Table S3 ) and CD45 barcoding to facilitate pooling of individuals [17] . Batch variability in staining was monitored through an internal biological control (online supplementary Figure S1 ). The debarcoded CD3 + CD4 + T cells were exported, normalized for cell events and the 31 markers dimensionally reduced with MarVis onto a bivariate X-Y axis through t-SNE (online supplementary Figure S2 ).
Clustering with k-means segregated the CD4 cells into distinct nodes ( Figure 1A) , and we detected an enrichment (p < 0.01) in node 22 for patients who will relapse, that represents CD4 + CD45RA -TNFɑ + IFNg -CD152 -PD1 -T cells (Figure 1A-C) . To ensure the results are not due to clustering artefacts, we manually gated the pre-clustering FCS files ( Figure 1D , gating strategy in online supplementary Figure S3 ), and determined significant (p < 0.05) upregulation in CD4 + CD45RAmemory subsets that was restricted within the TNFɑ + compartment. In particular, relapse patients were enriched for CD4 + CD45RA -TNFɑ + T cells which were absent for IFNg expression, and were notably deficient in immune checkpoints (PD1/CD152). We investigated the relationship of the dysregulated T effectors and immune checkpoint expression within the memory compartment ( Figure 1E ). There was a stronger positive correlation of CD45RA -TNFɑ + with CD45RA -CD152 -PD1 -(r = 0.8257) as opposed to CD45RA -CD152 + PD1 + (r = 0.5987) cells across the patients. The percentage of TNFɑ + cells Immunome perturbation in arthritic patients who relapse upon withdrawal 10 was significantly higher (p < 0.0001) in CD45RA -CD152 -/PD1cells ( Figure 1F ). While relapse patients showed a perceptible increase in T-effectors in the absence CD152/PD1, there was a marked drop to up-regulate CD152/PD1 as compared with remission patients ( Figure   1G -H).
CD4 + TNFɑ + healthy landscape unveils subclinical T-effector diversification in relapse patients
To validate the findings above and to investigate for the possibility of disease centric CD4 + cellular subsets that are masked by comparing JIA relapse/remission individuals, we included age-matched paediatric healthy controls. CD4 + TNFɑ + T cells from JIA relapse/remission (n=20) prior to withdrawal or healthy individuals (n=10) were compared to further delineate key differences within the T effector compartment. JIA patients who will relapse were enriched (p < 0.05) for node 17 against remission individuals (Figure 2A-B 
Overt T-effector diversification during flare manifestation and quiescence in stable remission
We have observed the presence of CD4 memory T cells in patients prior to relapse. To examine this phenomenon further, we interrogated the CD4 landscape of an independent batch of JIA individuals (n=16) withdrawn from therapy for 8 months, that either developed flare or remained in stable remission. Relapse (in flare) patients exhibited the emergence of a previously subclinical CD4 + CD45RA -TNFɑ + IL-6 + subset (Figure 3A-D 
Corresponding increase of memory Tregs and CD45RA -TNFɑ + prior to relapse
As Tregs have been previously implicated in JIA pathogenesis [10, 12, [18] [19] [20] , we examined their role in JIA patients prior/after therapy withdrawal (Figure 4A-B , gating strategy in online supplementary Figure S3 ). While no differential total Treg frequencies was detected, we observed higher levels of CD45RA -Treg (p < 0.0001) in JIA patients prior to relapse. We further verified this with t-SNE analysis of Tregs from relapse/remission patients prior to withdrawal, and determined an enrichment for CD45RA -CD152 + CD127 -Tregs for relapse individuals (Figure 4C-D) . Whilst no correlation (r=0.1532) with total Tregs was observed for CD45RA -TNFɑ + cells (Figure 4E) , there was a positive correlation (r=0.6017) with CD45RA -Treg.
Transcriptomic divergence in disease centric pathways that persists despite therapy
We have previously shown that JIA patients who developed active disease upon therapy withdrawal have stable epigenetic DNA CpG modifications in CD4 T cells that predisposed towards T cell activation and TCR signaling [14] . We wanted to investigate if CD4 memory T cells from JIA relapse/remission patients were differential in transcriptomic profile when their TCR is activated. We sorted for CD3 + CD4 + CD45RA -CD45RO + T cells (online supplementary Figure S4 ), stimulated 24hrs with anti-CD3/CD28, and profiled 579 immunological genes through Nanostring. Functional gene enrichment analysis (DAVID) of JIA relapse (n=6) or remission (n=6) patients versus healthy individuals (n=3) identified 5 common disease centric pathways that persisted from prior to after withdrawal of therapy (online supplementary Figure S5 and Table S4 -5). Dysregulation in UBE2L3, IL-6, STAT4, TYK2, TNFAIP3 and PTPN2 were found in both relapse and remission individuals, have been previously associated with JIA [21, 22] . We examined through Cytoscape and Reactome database for the gene associations involved in the 5 pathways (Figure 5A-E Table S3 and 6). Despite this overlap, we detected selective divergence within these pathways (Figure 5A-E) , with remission individuals Immunome perturbation in arthritic patients who relapse upon withdrawal 13 expressing higher levels of FYN, TNFRSF9, CASP1, TRAF1 and IKBKE which are involved in termination or resolution of these pathways [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
CD4 + CD45RA -TNFɑ + discriminates clinical fate prior to withdrawal of therapy We explored whether disease or remission duration of JIA patients (n=39) prior to study enrolment, could differentiate clinical fate, and found no significant difference between relapse or remission JIA patients (Figure 6A-D) . As we have shown that an inflammatory memory subset of CD4 + CD45RA -TNFɑ + is present in relapse individuals prior to therapy withdrawal, we tested whether this could afford for discrimination in clinical fate. There was a significant difference (p < 0.001) in the ratio of CD45RA -TNFɑ + /CD45RA + TNFɑ + cells in relapse as compared to remission individuals prior to therapy withdrawal, allowing for a ROC curve of AUC=0.9394 (Figure 6E-F) . As age could be a serious potential cofounder for immunological memory, we determined that in the relevant age groups (7-14 yrs), there was no significant difference in CD45RAor CD45RA -TNFɑ + cells among healthy individuals (n=56) (Figure 6G-H) . Relapse individuals had significantly higher CD45RA -TNFɑ + cells as compared across all the relevant age groups in healthy individuals (Figure 6H) .
Immunome perturbation in arthritic patients who relapse upon withdrawal 14
CONCLUSIONS
With a large proportion of JIA patients achieving clinical inactivity as a result of efficacious treatment with anti-TNFɑ biologics [2] , it becomes increasing pertinent to address the lack of definitive withdrawal guidelines. Here, we investigated with CyToF the heterogenous CD4 landscape of patients who achieved clinical inactivity prior to therapy withdrawal. We have identified for the first time an inflammatory CD4 memory subset (CD3 + CD4 + CD45RA -TNFɑ + ) that remains elevated in JIA patients prior to relapse, and could notably discriminate clinical fate prior to therapy withdrawal (AUC=0.939).
Remarkably the presence of this inflammatory subset despite therapy, was associated with a deficit in immune checkpoint (PD1 -CD152 -). This is consistent with the phenomenon of irAEs (rheumatic immune-related adverse events), where the application of immune checkpoint therapy (anti-PD1/anti-CD152) in cancer results in rheumatic diseases [33] . The presence of this inflammatory subset was further verified when we separately compared relapse against healthy non-JIA individuals. The CD4 + TNFɑ + healthy landscape helped reveal the subclinical diversification of T-effector mechanisms in relapse individuals, with the emergence of CD3 + CD4 + CD45RA -TNFɑ + PD1 -CD152 -T cells that are IL-6 + . Particularly, CD4 + CD45RA -T cells that are IL-6 + express higher levels of TNFɑ. Recently, a case series of 3 patients with cancer and developed severe polyarthritis following immune blockade therapy, reported successful treatment with tocilizumab (anti-IL-6) [34] . This reflects a level of commonality between inflammatory and disease resolution mechanisms operating in autoimmune disorders and cancer.
We further examined a separate cohort of JIA patients that developed flare or remained in remission 8 months into withdrawal of therapy, and verified the overt presence of T-effector diversification (CD45RA -TNFɑ + IL-6 + ) during flare. Whereas in patients that continue to remain in remission 8 months into withdrawal, there was no differential display of any CD45RA -TNFɑ + subsets as compared to the healthy CD4 landscape, though a CD4 + CXCR3 + CCR6 + subset was detected. It remains speculative if the CD4 + CXCR3 + CCR6 + subset seen in remission patients is an early disease driven subset or side-effect of therapy as it extends beyond the scope of the study, and will require longer follow-up duration. In rheumatoid arthritis, the CD4 + CXCR3 + CCR6 + subset is known express high levels of IFNg with poor secretion of IL-17A [35] , though we did not observe any associated cytokine profile in our remission patients.
In patients prior to relapse, the prevalence of the inflammatory CD4 + CD45RA -TNFɑ + T cells within the T-effector compartment is parallel by a corresponding increase in CD4 + CD45RA -CD152 + Tregs in the regulatory arm. This suggests there is a compensatory regulatory response towards subclinical inflammation prior to relapse, though it remains to be seen whether the suppression suffices or is defective. Others have shown that synovium Teffectors are resistant to Treg suppression [19] , which can be alleviated in JIA patients undergoing anti-TNFɑ therapy [36] . Though it is noted that in a subset of patients, in-vitro blockade of IL-6 + additionally alleviated T-effector resistance to Treg suppression [36] . 
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